Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)

Next Previous
Trial Profile

A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Carboplatin; Cisplatin; Dexamethasone; Folic acid; Vitamin B12 analogues
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-189
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 19 Sep 2024 This trial has been completed in Spain (Global end date: 2023-06-22) according to European Clinical Trials Database record.
  • 24 Jan 2024 This trial has been completed in Germany, according to the European Clinical Trials Database record.
  • 12 Sep 2023 Results of pooled analysis of 5-year outcomes , from KEYNOTE-407 China Extension, KEYNOTE-407, KEYNOTE-189 and KEYNOTE-189 Japan extension presented at the 24th World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top